Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CD46


Brief Information

Name:Membrane cofactor protein
Target Synonym:TLX,MCP,CD46,CD46 Molecule,Membrane Cofactor Protein (CD46, Trophoblast-Lymphocyte Cross-Reactive Antigen),Antigen Identified By Monoclonal Antibody TRA-2-10,CD46 Molecule, Complement Regulatory Protein,CD46 Antigen, Complement Regulatory Protein,Trophoblast Leukocyte Common Antigen,MIC10,Trophoblast-Lymphocyte Cross-Reactive Antigen,Complement Membrane Cofactor Protein,Trophoblast Leucocyte Common Antigen,Measles Virus Receptor,CD46 Antigen,TRA2.10,AHUS2,Membrane cofactor protein,MGC26544
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:3
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
CD6-H5254 Human Human CD46 Protein, Fc Tag (MALS verified)
CD6-H5226 Human Human CD46 Protein, His Tag
ACRO Quality

Part of Bioactivity data

CD46 MALS images

The purity of Human CD46 Protein, Fc Tag (Cat. No. CD6-H5254) is more than 90% and the molecular weight of this protein is around 85-105 kDa verified by SEC-MALS.

Synonym Name



Complement regulatory protein CD46 is also known as membrane Cofactor Protein (MCP), is a type I membrane protein and is a regulatory part of the complement system. CD46 is expressed by all cells except erythrocytes. MCP acts as a cofactor for complement factor I, a serine protease which protects autologous cells against complement-mediated injury by cleaving C3b and C4b deposited on host tissue, and also acts as a costimulatory factor for T-cells which induces the differentiation of CD4+ into T-regulatory 1 cells. In T-cells by binding to CD46, A number of viral and bacterial pathogens seem to exploit this property and directly induce an immunosuppressive phenotype. Defects in CD46 are a cause of susceptibility to hemolytic uremic syndrome atypical type 2 (AHUS2).

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
FOR-46 FOR-46; FG-3246 Phase 2 Clinical University Of California San Diego, Fortis Therapeutics Inc Prostatic Neoplasms, Castration-Resistant; Multiple Myeloma; Prostatic Neoplasms Details
Enadenotucirev ColoAd-1; Oncolytic Ad11/Ad3 Phase 1 Clinical Akamis Bio Ltd Ovarian Neoplasms; Rectal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Colonic Neoplasms; Neoplasms, Glandular and Epithelial; Urinary Bladder Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
YS-5 YS-5 Phase 1 Clinical Fortis Therapeutics Inc, United States Department Of Defense Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message